Patients with positive p-ERK expression in type II ovarian carcinomas tended to have a poor progression-free/overall survival; however, the difference was not statistically significant (p = 0.127, p = 0.087, respectively; Figure 2). The gene discussed is MAPK1; the disease is ovarian carcinoma.